Ilaria Pagani

Dr, PhD

  • 54 Citations
  • 5 h-Index
If you made any changes in Pure these will be visible here soon.

Personal profile

Public Profile

Dr. Ilaria S Pagani joined the Leukaemia Research Group at SAHMRI in July 2014, developing two projects on chronic myeloid leukaemia (CML). 

CML is a myeloproliferative disease characterize by the t(9;22)(q34;q11) balanced reciprocal translocation. The hallmark of the CML is the BCR/ABL1 fusion gene on Philadelphia chromosome (Ph), which encodes for a constitutively active protein tyrosine kinase (TK) that confers proliferative advantages to the Ph-positive clone. Tyrosine kinase inhibitors (TKIs) dramatically improved the survival of chronic myeloid leukaemia (CML) patients. TK inhibitors (TKIs) have revolutionized the management of the CML, providing target therapy for patients. Despite the success of TKIs in long-term survival, variations in treatment outcome suggest a possible secondary mechanism of resistance due to the persistence of a pre-existing clone that had acquired additional genetic lesions. The first project is the characterization of the genomic landscape of mitochondrial (mt) DNA mutations in CML by next generation sequencing techniques, identifying a sub-group of patients that respond well to therapy. Next goal will be to determine whether mtDNA mutations influence the susceptibility of CML cells to undergo apoptosis in response to tyrosine kinase inhibition. 

Even if 50% of patients who achieved a deep molecular response and maintain it for 2 years can stop TKIs without relapsing, about half of patients experience molecular relapse. The second project is the investigation of whether lineage and proliferative potential of residual leukaemia are key determinants of treatment free remission after stopping therapy in comparison with relapse patients.

External positions

Affiliated Lecturer, University of Adelaide

1 Nov 2017 → …

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2010 2019

  • 54 Citations
  • 5 h-Index
  • 8 Article
  • 3 Comment/debate
  • 1 Letter

Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia

Ross, D. M., Pagani, I., Irani, Y., Clarson, J., Gray, T., Dang, Y., McLean, J., Saunders, V., Carne, L., Reynolds, J., Ritchie, D. S., White, D., Branford, S., Hughes, T. & Yong, A., 1 Aug 2019, In : British Journal of Haematology. 186, 3, p. e56-e60

Research output: Contribution to journalLetter

5 Citations (Scopus)

BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia

Pagani, I. S., Dang, P., Kommers, I. O., Goyne, J. M., Nicola, M., Saunders, V. A., Braley, J., White, D. L., Yeung, D. T., Branford, S., Hughes, T. P. & Ross, D. M., 30 Nov 2018, In : Haematologica. 103, 12, p. 2026-2032 7 p.

Research output: Contribution to journalArticle

Open Access
1 Citation (Scopus)

Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells

on behalf of the Australasian Leukaemia and Lymphoma Group (ALLG), 1 Dec 2018, In : Leukemia. 32, 12, p. 2572-2579 8 p.

Research output: Contribution to journalArticle

4 Citations (Scopus)

gDNA Q-PCR for clinical monitoring of CML

Porta, G., Pagani, I. & Pirrone, C., 1 Jan 2015, In : Cell Cycle. 14, 23, p. 3659-3660 2 p.

Research output: Contribution to journalArticle